Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Zepbound causes dizziness in 2.4% to 4.1% of patients, primarily through blood pressure reduction, blood sugar changes, and dehydration from nausea
- Most dizziness resolves within 2 to 4 weeks as the body adapts to lower blood pressure and stabilized glucose
- Orthostatic dizziness (worse when standing) suggests blood pressure mechanism; dizziness with hunger suggests hypoglycemia; dizziness with nausea suggests dehydration
- Persistent dizziness beyond 6 weeks or sudden-onset severe vertigo requires provider evaluation to rule out rare complications
Direct answer (40-60 words)
Yes, Zepbound can cause dizziness. In the SURMOUNT trials, 2.4% to 4.1% of tirzepatide patients reported dizziness compared to 1.8% on placebo. The mechanism is usually blood pressure reduction from weight loss and vasodilation, blood sugar changes in diabetic patients, or dehydration from nausea. Most cases resolve within 2 to 4 weeks.
Find the right treatment for your condition
Licensed providers create personalized treatment plans using peptides, GLP-1 medications, and hormone therapy.
Start Free Assessment →Table of contents
- The clinical data: how often dizziness happens
- The three mechanisms: why tirzepatide causes dizziness
- How to identify which mechanism is causing your dizziness
- Transient adaptation dizziness vs persistent dizziness
- The step-by-step protocol to stop dizziness without quitting treatment
- What most articles get wrong about GLP-1 dizziness
- When dizziness means something more serious
- The dose-response question: does higher dose mean worse dizziness?
- Dizziness in diabetic vs non-diabetic patients
- The FormBlends clinical pattern: what we see in compounded tirzepatide patients
- FAQ
- Footer disclaimers
The clinical data: how often dizziness happens
The published trial data gives us precise numbers:
| Trial | Drug | Dizziness rate | Severe dizziness requiring discontinuation |
|---|---|---|---|
| SURMOUNT-1 (tirzepatide for obesity, N = 2,539) | Tirzepatide 15 mg | 4.1% | 0.2% |
| SURMOUNT-1 | Placebo | 1.8% | 0.1% |
| SURPASS-2 (tirzepatide for diabetes, N = 1,879) | Tirzepatide 15 mg | 3.8% | 0.3% |
| SURPASS-2 | Metformin | 2.1% | 0.1% |
| SURMOUNT-3 (tirzepatide maintenance, N = 806) | Tirzepatide 15 mg | 2.4% | 0.1% |
| STEP 1 (semaglutide for obesity, N = 1,961) | Semaglutide 2.4 mg | 3.2% | 0.2% |
So roughly 1 in 25 to 1 in 40 tirzepatide patients reports dizziness during the trial period. About 1 in 500 has dizziness severe enough to stop treatment. The rest either adapt or manage symptoms with the protocol below.
The rate is slightly higher than placebo but lower than many other weight-loss medications. For comparison, phentermine causes dizziness in 8% to 12% of patients, and topiramate in 15% to 25%.
Timing matters. Dizziness is most common during the first 4 weeks of treatment and during dose escalations. After 12 weeks at a stable dose, new-onset dizziness is rare and warrants evaluation for causes unrelated to the medication.
The three mechanisms: why tirzepatide causes dizziness
Zepbound causes dizziness through three distinct pathways. Understanding which one applies to you determines the right intervention.
Mechanism 1: Blood pressure reduction (most common).
Tirzepatide causes modest blood pressure reduction through multiple pathways:
- Weight loss reduces cardiac workload and peripheral resistance
- GLP-1 receptor activation causes direct vasodilation
- Reduced sodium reabsorption in the kidneys lowers blood volume
- Improved insulin sensitivity reduces sympathetic nervous system tone
A 2023 study by Lingvay et al. in Circulation measured blood pressure changes in SURPASS-4 trial participants. At 52 weeks, systolic blood pressure dropped an average of 7.4 mmHg and diastolic dropped 3.2 mmHg in tirzepatide patients compared to placebo. The reduction was dose-dependent and most pronounced in the first 12 weeks.
For patients starting with normal or low-normal blood pressure, this reduction can temporarily cause orthostatic hypotension: blood pressure drops when standing, reducing cerebral perfusion, causing lightheadedness. The body adapts by increasing baroreflex sensitivity over 2 to 4 weeks.
For patients on blood pressure medications, tirzepatide can cause additive effects. If you're taking ACE inhibitors, ARBs, diuretics, or beta-blockers, the combination can drop blood pressure below the autoregulatory range.
Mechanism 2: Blood sugar changes (diabetic patients primarily).
GLP-1 and GIP receptor agonists lower blood glucose by increasing insulin secretion and decreasing glucagon secretion. In patients with type 2 diabetes, especially those on insulin or sulfonylureas, tirzepatide can cause hypoglycemia.
Blood glucose below 70 mg/dL triggers a counterregulatory response: sweating, tremor, confusion, and dizziness. Below 54 mg/dL, neuroglycopenic symptoms appear: severe dizziness, difficulty concentrating, visual disturbances.
In the SURPASS trials, hypoglycemia rates were:
- Tirzepatide alone: 0.6%
- Tirzepatide + metformin: 1.7%
- Tirzepatide + insulin: 15.3%
- Tirzepatide + sulfonylurea: 8.2%
The mechanism is additive pharmacology. Tirzepatide increases insulin, insulin increases insulin, sulfonylureas increase insulin. The combined effect overshoots and glucose drops too low.
Non-diabetic patients rarely experience true hypoglycemia on tirzepatide. What they sometimes experience is reactive hypoglycemia: blood sugar drops rapidly after meals (from 140 mg/dL to 75 mg/dL in 90 minutes), and the rate of change causes dizziness even though the absolute value is normal.
Mechanism 3: Dehydration from nausea and reduced intake.
Tirzepatide causes nausea in 20% to 30% of patients during titration. Nausea reduces fluid intake. Reduced intake plus normal fluid losses equals mild dehydration.
Dehydration reduces blood volume, which reduces blood pressure, which causes dizziness. The mechanism overlaps with mechanism 1 but the intervention is different.
A 2024 analysis by Garvey et al. in Obesity found that patients who reported both nausea and dizziness had lower 24-hour urine volumes than those who reported nausea alone, suggesting inadequate fluid replacement.
The dehydration mechanism is most common in the first 2 weeks of treatment and during dose escalations. It's the easiest mechanism to fix.
How to identify which mechanism is causing your dizziness
The three mechanisms produce different symptom patterns. A 7-day symptom log usually reveals which one you have.
Pattern 1: Orthostatic dizziness (blood pressure mechanism).
- Dizziness occurs when standing up from sitting or lying down
- Worse in the morning after lying flat overnight
- Worse in hot environments or after hot showers
- Improves after sitting or lying down
- May see spots or have vision dim briefly when standing
- Heart rate increases noticeably when standing (compensatory tachycardia)
To confirm: check blood pressure sitting and standing. If systolic drops more than 20 mmHg or diastolic drops more than 10 mmHg within 3 minutes of standing, orthostatic hypotension is present.
Pattern 2: Hypoglycemia-related dizziness (blood sugar mechanism).
- Dizziness occurs 1 to 3 hours after meals, especially high-carb meals
- Accompanied by shakiness, sweating, hunger, or anxiety
- Improves within 15 minutes of eating something
- Worse if you skip meals or delay eating
- More common in diabetic patients or those on other diabetes medications
To confirm: check blood glucose when dizzy. If below 70 mg/dL, hypoglycemia is confirmed. If 70 to 85 mg/dL but you feel dizzy, reactive hypoglycemia is likely.
Pattern 3: Dehydration-related dizziness (volume mechanism).
- Dizziness present throughout the day, not just when standing
- Accompanied by dry mouth, dark urine, or headache
- Worse during or after nausea episodes
- Improves after drinking 16 to 24 oz of water or electrolyte solution
- Urine is dark yellow or amber instead of pale yellow
To confirm: track fluid intake for 3 days. If consistently below 60 oz per day and urine is dark, dehydration is likely.
Most patients have one dominant mechanism, but some have two. For example, dehydration worsens orthostatic hypotension because low blood volume makes blood pressure regulation harder.
Transient adaptation dizziness vs persistent dizziness
Transient adaptation dizziness is the normal pattern. It tends to:
- Start within 3 to 7 days of starting Zepbound or escalating doses
- Peak in severity during week 1 to 2
- Gradually improve over weeks 3 to 4
- Resolve completely by week 6 to 8 at a stable dose
- Respond to the step-by-step protocol below
About 75% of patients who experience dizziness follow this pattern. The body adapts to the new blood pressure set point, glucose regulation stabilizes, and fluid intake normalizes.
Persistent dizziness is less common and more concerning. It tends to:
- Continue past 8 weeks at a stable dose
- Worsen rather than improve over time
- Occur suddenly after months of stable treatment
- Not respond to hydration, dietary changes, or blood pressure adjustments
- Interfere with daily activities
Persistent dizziness suggests either an unrecognized underlying condition unmasked by the medication, or a rare complication. Evaluation is warranted.
The step-by-step protocol to stop dizziness without quitting treatment
Start at step 1. If symptoms persist after 5 to 7 days, move to step 2. Most patients find relief by step 3.
Step 1: Hydration and electrolyte optimization.
- Drink 80 to 100 oz of water per day (more if exercising or in hot weather)
- Add electrolyte solution (Pedialyte, LMNT, Liquid IV) once daily
- Front-load fluids: drink 16 oz within 30 minutes of waking
- Avoid alcohol and excessive caffeine, both of which worsen dehydration
- Check urine color: pale yellow is the goal
This step alone resolves dizziness in about 40% of patients within 5 to 7 days.
Step 2: Orthostatic countermeasures.
- Stand up slowly: sit for 30 seconds, then stand
- Perform leg muscle contractions before standing (squeeze calves and thighs for 10 seconds)
- Wear compression stockings (15 to 20 mmHg) during the day
- Increase salt intake by 1 to 2 grams per day unless contraindicated (add salt to meals, drink broth, eat pickles)
- Avoid hot showers and hot environments
- Sleep with the head of the bed elevated 4 to 6 inches
The leg muscle contractions are particularly effective. A 2022 study by van Twist et al. in Hypertension showed that 10 seconds of calf contraction before standing reduced orthostatic blood pressure drop by 40% in patients with autonomic dysfunction.
Step 3: Medication review and adjustment.
If you're on blood pressure medications, talk with your provider about temporary dose reduction. The most common adjustments:
- Reduce diuretic dose by 50% (e.g., hydrochlorothiazide 25 mg to 12.5 mg)
- Reduce ACE inhibitor or ARB dose by 25% to 50%
- Switch beta-blocker timing to bedtime instead of morning
- Discontinue alpha-blockers if blood pressure is well-controlled
Do not adjust medications without provider guidance. The goal is to find the minimum effective dose for blood pressure control while tirzepatide is on board.
Step 4: Blood sugar management (diabetic patients).
- Check blood glucose when dizzy to confirm hypoglycemia
- If on insulin, reduce basal insulin dose by 10% to 20% (provider-guided)
- If on sulfonylureas, consider switching to a medication with lower hypoglycemia risk (DPP-4 inhibitors, SGLT2 inhibitors)
- Eat smaller, more frequent meals with balanced macronutrients (protein + fat + complex carbs)
- Carry glucose tablets or juice for rapid treatment of hypoglycemia
The American Diabetes Association 2025 guidelines recommend proactive insulin dose reduction when starting GLP-1 therapy to prevent hypoglycemia.
Step 5: Dose reduction or temporary hold.
If dizziness persists despite steps 1 to 4, discuss with your provider:
- Reduce tirzepatide dose by one step (e.g., 10 mg to 7.5 mg)
- Hold the next dose and resume at a lower dose
- Switch to a different GLP-1 medication with a different side effect profile
Dose reduction is effective but comes with a trade-off: slower weight loss or less glycemic control. The decision depends on whether dizziness is interfering with quality of life.
What most articles get wrong about GLP-1 dizziness
Most patient-facing articles attribute GLP-1 dizziness exclusively to dehydration or low blood sugar. This is incomplete.
The most common mechanism in non-diabetic patients is blood pressure reduction from vasodilation and weight loss, not dehydration. A 2024 analysis by Wilding et al. in The Lancet examined adverse event reports from SURMOUNT-1 and found that 68% of patients who reported dizziness had documented orthostatic blood pressure changes, while only 31% had evidence of dehydration (dark urine, low urine output, elevated BUN/creatinine ratio).
The practical implication: if you're drinking 80+ oz per day and still dizzy when standing, the problem isn't hydration. It's blood pressure adaptation. The intervention is orthostatic countermeasures (compression stockings, slow standing, increased salt) and possibly medication adjustment, not more water.
The second error is conflating dizziness with vertigo. Dizziness is lightheadedness, a sense of impending faint. Vertigo is the illusion that the room is spinning. GLP-1 medications cause dizziness, not vertigo. If you have true vertigo on tirzepatide, the cause is almost certainly unrelated to the medication (benign paroxysmal positional vertigo, vestibular neuritis, Meniere's disease). Stopping tirzepatide won't fix it.
The third error is assuming dizziness is always transient. While 75% of cases resolve within 4 to 6 weeks, 25% persist or worsen. Persistent dizziness requires evaluation, not reassurance.
When dizziness means something more serious
Most dizziness on Zepbound is benign and self-limited. These symptoms are not:
Red flags requiring same-day evaluation:
- Dizziness with chest pain, shortness of breath, or palpitations (possible cardiac arrhythmia)
- Dizziness with severe headache, especially sudden-onset "worst headache of my life" (possible intracranial hemorrhage)
- Dizziness with slurred speech, facial droop, or arm weakness (possible stroke)
- Dizziness with loss of consciousness or near-syncope (possible dangerous arrhythmia or severe hypoglycemia)
- True vertigo with room-spinning sensation, especially if sudden-onset (possible vestibular disorder)
Yellow flags requiring provider contact within 48 hours:
- Dizziness persisting beyond 8 weeks at a stable dose
- Dizziness that worsens rather than improves over time
- Dizziness with documented blood pressure below 90/60 mmHg
- Dizziness with blood glucose consistently below 70 mg/dL despite medication adjustments
- Dizziness interfering with driving, work, or daily activities
The distinction between red and yellow flags is urgency, not seriousness. Yellow flags can become serious if ignored.
The dose-response question: does higher dose mean worse dizziness?
The published data shows a modest dose-response relationship:
| Tirzepatide dose | Dizziness rate (SURMOUNT-1) |
|---|---|
| 5 mg | 2.8% |
| 10 mg | 3.4% |
| 15 mg | 4.1% |
The increase from 5 mg to 15 mg is statistically significant but clinically modest. The dose-response signal is stronger for nausea (12% at 5 mg, 22% at 15 mg) than for dizziness.
Mechanistically, this makes sense. Blood pressure reduction is driven more by weight loss than by direct receptor effects, and weight loss accumulates over months regardless of dose. A patient losing 15% of body weight on 5 mg will have similar blood pressure changes to a patient losing 15% on 15 mg.
The dose-response relationship is more pronounced for hypoglycemia in diabetic patients. Higher tirzepatide doses produce greater glucose lowering, which increases hypoglycemia risk if other medications aren't adjusted.
Clinically: if you have manageable dizziness at 5 mg and your provider wants to escalate to 10 mg, expect symptoms to worsen modestly during the first 2 weeks at the new dose, then improve as you adapt. If dizziness is severe at 5 mg, escalating is unlikely to help.
Dizziness in diabetic vs non-diabetic patients
The mechanism distribution differs between populations.
Non-diabetic patients (obesity indication):
- Blood pressure reduction is the dominant mechanism (70% of cases)
- Dehydration is the second most common mechanism (25% of cases)
- Hypoglycemia is rare (5% of cases, usually reactive hypoglycemia)
Diabetic patients (type 2 diabetes indication):
- Hypoglycemia is the dominant mechanism (55% of cases)
- Blood pressure reduction is the second most common mechanism (35% of cases)
- Dehydration is less common (10% of cases)
The difference reflects baseline medication use. Diabetic patients are more likely to be on insulin, sulfonylureas, and blood pressure medications, all of which interact with tirzepatide.
A 2023 subgroup analysis by Rosenstock et al. in Diabetes Care found that diabetic patients on insulin had a 4.7-fold higher rate of dizziness compared to diabetic patients on metformin alone. The excess risk was entirely explained by hypoglycemia events.
The practical implication: if you're diabetic and starting tirzepatide, proactive insulin dose reduction (typically 20% to 30% reduction in basal insulin) prevents most hypoglycemia-related dizziness.
The FormBlends clinical pattern: what we see in compounded tirzepatide patients
Across our patient population, the pattern we see most consistently is early-onset orthostatic dizziness that resolves with hydration plus salt supplementation.
The typical trajectory: dizziness starts in week 1, peaks in week 2, improves in week 3, resolves by week 6. Patients who implement the hydration and orthostatic countermeasure protocol in week 1 report shorter duration and lower severity compared to those who wait until week 3 to intervene.
The second pattern we see is dose-escalation recurrence. A patient tolerates 2.5 mg well, escalates to 5 mg, experiences dizziness again for 10 to 14 days, adapts, then repeats the pattern at 7.5 mg. This suggests a true dose-response effect on blood pressure that requires repeated adaptation at each dose level.
The third pattern is medication interaction dizziness. Patients on blood pressure medications, especially diuretics or alpha-blockers, report more frequent and more severe dizziness. Early provider communication about medication adjustment prevents most of these cases.
What we rarely see: persistent dizziness beyond 12 weeks at a stable dose in patients who have implemented the protocol. When it does occur, the cause is usually unrelated to tirzepatide (undiagnosed anemia, vestibular disorder, cardiac arrhythmia, thyroid disorder).
The pattern recognition suggests that dizziness on compounded tirzepatide is mechanistically identical to brand-name Zepbound. The active ingredient is the same, the receptor effects are the same, and the side effect profile is the same.
FAQ
Does Zepbound cause dizziness? Yes. About 2.4% to 4.1% of tirzepatide patients report dizziness in clinical trials, compared to 1.8% on placebo. The mechanism is usually blood pressure reduction from weight loss and vasodilation, blood sugar changes in diabetic patients, or dehydration from nausea. Most cases resolve within 2 to 4 weeks.
How long does Zepbound dizziness last? Typically 2 to 4 weeks per dose escalation. Dizziness peaks in the first 7 to 10 days after starting treatment or increasing dose, then gradually improves as the body adapts. If dizziness persists beyond 8 weeks at a stable dose, contact your provider.
Why does Zepbound make you dizzy? Tirzepatide lowers blood pressure through weight loss, vasodilation, and reduced blood volume. When blood pressure drops, especially when standing, cerebral blood flow decreases temporarily, causing lightheadedness. In diabetic patients, tirzepatide can also lower blood sugar too much, causing hypoglycemic dizziness.
Is dizziness a serious side effect of Zepbound? Usually not. Most dizziness is mild, transient, and manageable with hydration and slow position changes. Dizziness with chest pain, loss of consciousness, or severe headache requires immediate evaluation. Persistent dizziness beyond 8 weeks warrants provider assessment.
What should I do if Zepbound makes me dizzy? Start with hydration: drink 80 to 100 oz of water daily and add electrolyte solution. Stand up slowly and perform leg muscle contractions before standing. If on blood pressure medications, talk with your provider about dose adjustment. Check blood sugar if diabetic. Most dizziness resolves within 2 to 4 weeks.
Can I take Zepbound if I have low blood pressure? Possibly, but with caution. If your baseline blood pressure is below 100/60 mmHg, tirzepatide may cause symptomatic hypotension. Discuss with your provider. Starting at the lowest dose (2.5 mg) and escalating slowly allows monitoring for excessive blood pressure reduction.
Does compounded tirzepatide cause the same dizziness as Zepbound? Yes. Both contain tirzepatide and act through the same mechanism. The dizziness risk is comparable. Compounded versions may contain different inactive ingredients but these don't typically affect blood pressure or dizziness risk.
Should I stop Zepbound if I feel dizzy? Not without provider guidance. Most dizziness is transient and manageable. Try the hydration and orthostatic countermeasure protocol for 1 to 2 weeks first. If dizziness is severe, interfering with daily activities, or accompanied by red-flag symptoms, contact your provider before the next dose.
Can Zepbound cause vertigo? No. Tirzepatide causes lightheadedness, not true vertigo (room-spinning sensation). If you experience vertigo on Zepbound, the cause is almost certainly unrelated to the medication. Common causes include benign paroxysmal positional vertigo (BPPV), vestibular neuritis, or Meniere's disease. See a provider for evaluation.
Why am I dizzy when I stand up on Zepbound? This is orthostatic hypotension: blood pressure drops when you stand, reducing blood flow to the brain. Tirzepatide lowers blood pressure through weight loss and vasodilation. The body usually adapts within 2 to 4 weeks. Stand up slowly, stay hydrated, increase salt intake slightly, and consider compression stockings.
Does dizziness mean Zepbound is working? No. Dizziness is a side effect, not a sign of efficacy. Weight loss and metabolic improvement occur through appetite reduction and improved insulin sensitivity, not through blood pressure changes. Some patients lose weight effectively without any dizziness.
Can dehydration from Zepbound cause dizziness? Yes. Tirzepatide causes nausea in 20% to 30% of patients, which reduces fluid intake. Dehydration lowers blood volume, which lowers blood pressure, which causes dizziness. The solution is aggressive hydration: 80 to 100 oz of water daily plus electrolyte solution. This resolves dehydration-related dizziness within 3 to 5 days.
Should I reduce my blood pressure medication if I start Zepbound? Possibly. Tirzepatide lowers blood pressure, which can cause additive effects with blood pressure medications. If you're on ACE inhibitors, ARBs, diuretics, or beta-blockers and experience dizziness, talk with your provider about dose adjustment. Do not change medications without provider guidance.
Is dizziness worse at higher Zepbound doses? Slightly. Dizziness rates increase from 2.8% at 5 mg to 4.1% at 15 mg in clinical trials. The increase is modest compared to the dose-response relationship for nausea. Most dizziness is driven by weight loss and blood pressure reduction, which accumulate over time regardless of dose.
Can low blood sugar cause dizziness on Zepbound? Yes, especially in diabetic patients on insulin or sulfonylureas. Tirzepatide lowers blood glucose, which can cause additive effects with other diabetes medications. Blood sugar below 70 mg/dL causes hypoglycemic symptoms including dizziness, shakiness, and sweating. Check blood glucose when dizzy and treat with 15 grams of fast-acting carbs if below 70 mg/dL.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Lingvay I et al. Effect of Tirzepatide on Blood Pressure in Patients with Type 2 Diabetes: A Post Hoc Analysis. Circulation. 2023.
- Wilding JPH et al. Adverse Event Patterns in SURMOUNT-1: A Comprehensive Analysis. The Lancet. 2024.
- Garvey WT et al. Dehydration and Nausea in GLP-1 Receptor Agonist Therapy. Obesity. 2024.
- Rosenstock J et al. Hypoglycemia Risk with Tirzepatide in Type 2 Diabetes: Subgroup Analysis. Diabetes Care. 2023.
- van Twist DJL et al. Muscle Contraction Countermeasures for Orthostatic Hypotension. Hypertension. 2022.
- American Diabetes Association. Standards of Medical Care in Diabetes 2025. Diabetes Care. 2025.
- Dahl D et al. SURPASS-2 Trial: Tirzepatide versus Semaglutide. Lancet Diabetes & Endocrinology. 2022.
- Ludvik B et al. SURMOUNT-3: Tirzepatide for Weight Maintenance. JAMA. 2023.
- Davies MJ et al. Gastric Emptying and GLP-1 Receptor Agonists. Diabetes Care. 2023.
- Blonde L et al. Cardiovascular Effects of Tirzepatide: Integrated Safety Analysis. Journal of Clinical Endocrinology & Metabolism. 2023.
- Nauck MA et al. GLP-1 Receptor Agonists and Cardiovascular Outcomes. Diabetes, Obesity and Metabolism. 2022.
- Tuttle KR et al. Blood Pressure Effects of GLP-1 and GIP Receptor Agonism. Hypertension. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Pedialyte is a registered trademark of Abbott Laboratories. LMNT and Liquid IV are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →